Overview of Ultima-Tirzepatide 10 mg
Ultima-Tirzepatide 10 mg is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Ultima Peptides for in-vitro research applications. This synthetic peptide represents a novel class of dual incretin receptor agonists, enabling researchers to investigate complex metabolic pathways and glucose homeostasis mechanisms. The compound demonstrates high binding affinity for both GIP and GLP-1 receptors, making it valuable for studying incretin biology and metabolic regulation in laboratory models. Researchers at Stroid UK Shop utilise this compound to examine dual incretin pathway activation and its effects on cellular metabolism.
Research Applications and Mechanisms
Tirzepatide functions through simultaneous activation of GIP and GLP-1 receptors, providing researchers with a unique tool to study dual incretin signalling pathways. In preclinical models, the compound has been investigated for its effects on insulin secretion, glucagon suppression, and gastric emptying modulation. The dual mechanism allows for comprehensive examination of incretin hormone interactions and their downstream metabolic effects. Research teams studying metabolic regulation compounds often incorporate tirzepatide into their protocols to examine glucose homeostasis and energy expenditure pathways. The peptide’s structure enables examination of receptor selectivity and tissue-specific responses across various experimental models. Additionally, researchers analyse the compound alongside other research peptides to understand comparative efficacy in metabolic studies.
Specification and Storage Details
| Parameter | Value |
|---|---|
| Product Name | Ultima-Tirzepatide 10 mg |
| Manufacturer | Ultima Peptides |
| Molecular Formula | Verify with supplier |
| Molecular Weight | Verify with supplier |
| CAS Number | Verify with supplier |
| Purity | Verify with COA |
| Storage | Lyophilised: -20°C, Reconstituted: 2-8°C |
| Stability | Use within 30 days when reconstituted |
Proper storage protocols ensure compound stability throughout research periods. Lyophilised powder should be stored at -20°C in original packaging, while reconstituted solutions require refrigeration at 2-8°C and should be used within 30 days. Researchers examining selective modulators often compare storage requirements across different compound classes to optimise laboratory protocols.
Research Compliance and Safety
Ultima-Tirzepatide 10 mg is manufactured exclusively for laboratory research applications and in-vitro studies. This product is not intended for human consumption, therapeutic use, or any clinical applications. Researchers must ensure appropriate institutional approvals and safety protocols are in place before commencing studies. All handling should occur within properly equipped laboratory facilities with adequate ventilation and safety measures. The compound should only be used by qualified research personnel familiar with peptide handling procedures and safety requirements for synthetic hormone analogues.
